Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology ...

Researchers developed a CRISPR and single-molecule microarray test that quantifies Candida auris and detects antifungal ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...

One of the most inherent risks is the risk of damaging healthy genes. This rather brutal issue is step one of risk management. It also means large sequences of amino acids that must be checked, ...

If I were to locate the moment AI slop broke through into popular consciousness, I’d pick the video of rabbits bouncing on a trampoline that went viral last summer. For many savvy internet users, ...

Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act like molecular anchors. The work confirms these tags actively silence genes, ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the ...